Cargando…
Radiation therapy for primary orbital and ocular adnexal lymphoma
OBJECTIVE: To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL) METHODS: Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637715/ https://www.ncbi.nlm.nih.gov/pubmed/36353653 http://dx.doi.org/10.1016/j.ctro.2022.10.001 |
_version_ | 1784825248062898176 |
---|---|
author | Pereira-Da Silva, Maria Valeria Di Nicola, Maria Laura Altomare, Filiberto Xu, Wei Tsang, Richard Laperriere, Normand Krema, Hatem |
author_facet | Pereira-Da Silva, Maria Valeria Di Nicola, Maria Laura Altomare, Filiberto Xu, Wei Tsang, Richard Laperriere, Normand Krema, Hatem |
author_sort | Pereira-Da Silva, Maria Valeria |
collection | PubMed |
description | OBJECTIVE: To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL) METHODS: Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radiotherapy between 2003 and 2015. Patient demographics, tumour extent and pathology, radiotherapy techniques, and treatment outcomes were reviewed. The actuarial rates of tumour control and radiation toxicities were calculated using Kaplan-Meier estimates. RESULTS: This study included 167 tumours, of which MALT lymphoma involved 149 (89 %). The conjunctiva and orbit were equally involved as the predominant site (48 %). Megavoltage photon radiotherapy was used in 60 % of predominantly orbital lymphoma and Electron beam with lens shielding in 77 % of the conjunctival lymphoma. The majority (95 %) were treated with a total dose of 25 Gy in 10 fractions. Local control rate was 98 % (CI: 93–100 %) at 5 years. The long-term RT toxicities included dry eye in 27 eyes (16 %) and cataract in 22 (13 %). None of the patients developed significant structural or functional radiation toxicity. CONCLUSION: External Beam Radiotherapy, with lens shielding whenever indicated, at a dose of 20–30 Gy delivered over 10–20 fractions is an efficacious and safe primary treatment option for POOAL lymphoma, with excellent local control and low incidence of late manageable ocular toxicities. |
format | Online Article Text |
id | pubmed-9637715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96377152022-11-08 Radiation therapy for primary orbital and ocular adnexal lymphoma Pereira-Da Silva, Maria Valeria Di Nicola, Maria Laura Altomare, Filiberto Xu, Wei Tsang, Richard Laperriere, Normand Krema, Hatem Clin Transl Radiat Oncol Article OBJECTIVE: To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL) METHODS: Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radiotherapy between 2003 and 2015. Patient demographics, tumour extent and pathology, radiotherapy techniques, and treatment outcomes were reviewed. The actuarial rates of tumour control and radiation toxicities were calculated using Kaplan-Meier estimates. RESULTS: This study included 167 tumours, of which MALT lymphoma involved 149 (89 %). The conjunctiva and orbit were equally involved as the predominant site (48 %). Megavoltage photon radiotherapy was used in 60 % of predominantly orbital lymphoma and Electron beam with lens shielding in 77 % of the conjunctival lymphoma. The majority (95 %) were treated with a total dose of 25 Gy in 10 fractions. Local control rate was 98 % (CI: 93–100 %) at 5 years. The long-term RT toxicities included dry eye in 27 eyes (16 %) and cataract in 22 (13 %). None of the patients developed significant structural or functional radiation toxicity. CONCLUSION: External Beam Radiotherapy, with lens shielding whenever indicated, at a dose of 20–30 Gy delivered over 10–20 fractions is an efficacious and safe primary treatment option for POOAL lymphoma, with excellent local control and low incidence of late manageable ocular toxicities. Elsevier 2022-10-08 /pmc/articles/PMC9637715/ /pubmed/36353653 http://dx.doi.org/10.1016/j.ctro.2022.10.001 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Pereira-Da Silva, Maria Valeria Di Nicola, Maria Laura Altomare, Filiberto Xu, Wei Tsang, Richard Laperriere, Normand Krema, Hatem Radiation therapy for primary orbital and ocular adnexal lymphoma |
title | Radiation therapy for primary orbital and ocular adnexal lymphoma |
title_full | Radiation therapy for primary orbital and ocular adnexal lymphoma |
title_fullStr | Radiation therapy for primary orbital and ocular adnexal lymphoma |
title_full_unstemmed | Radiation therapy for primary orbital and ocular adnexal lymphoma |
title_short | Radiation therapy for primary orbital and ocular adnexal lymphoma |
title_sort | radiation therapy for primary orbital and ocular adnexal lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637715/ https://www.ncbi.nlm.nih.gov/pubmed/36353653 http://dx.doi.org/10.1016/j.ctro.2022.10.001 |
work_keys_str_mv | AT pereiradasilvamariavaleria radiationtherapyforprimaryorbitalandocularadnexallymphoma AT dinicolamarialaura radiationtherapyforprimaryorbitalandocularadnexallymphoma AT altomarefiliberto radiationtherapyforprimaryorbitalandocularadnexallymphoma AT xuwei radiationtherapyforprimaryorbitalandocularadnexallymphoma AT tsangrichard radiationtherapyforprimaryorbitalandocularadnexallymphoma AT laperrierenormand radiationtherapyforprimaryorbitalandocularadnexallymphoma AT kremahatem radiationtherapyforprimaryorbitalandocularadnexallymphoma |